References
- 1. Micallef JM, Kaldor JM and Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. 2006 J. Viral Hepatitis, 13:34-41.
- 2. Verna EC, Brown RS Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006;10(4):919-40.
- 3. Civan J, Hann HW. Hepatitis C Virus Mediated Hepatocellular Carcinoma: A Focused Review for a Time of Changing Therapeutic Options. N A J Med Sci. 2014;7(1):8-16.
- 4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562.
- 5. Kiprijanovska S, Davalieva K, Novevski P, et al. Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: a 5 years survey. J Med Virol 2013;85(12):2072-8.
- 6. Samreen B, Khaliq S, Ashfag UA, et al. Hepatitis C virus entry: role of host and viral factors. Infect Genet Evol. 2012; 12(8):1699-709.
- 7. Dzekova-Vidimliski P, Nikolov I, Matevska-Geshkovska N, et al. Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci 2015; 15(4):55-9.
- 8. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009; 29 (Suppl 1): 15-18.
- 9. Yu JW, Sun LJ, Liu W, et al. Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway. Int J Infect Dis 2013; 17(7):e539-45.
- 10. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection:does it matter? Journal of hepatology, 2012; 56(1)S56-S65.
- 11. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.
- 12. Grassi G, Di Caprio G, Fimia et al. Hepatitis C virus relies on lipoproteins for its life cycle. World J Gastroenterol 2016; 22(6): 1953-1965.
- 13. Bassendine MF, Sheridan DA, Bridge SH, et al. Lipids and HCV. Semin Immunopathol. 2013; 35: 87-100.
- 14. Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflamatory organ in human disease. Endocr Rev 2006; 27: 449-67.
- 15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
- 16. Wu Q, Zhan FY, Chen EQ, et al. Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China.Hepatitis Monthly. 2015;15(6):e28836.
- 17. Chuang W-L, Yu M-L. Host factors determining the efficacy of hepatitis C treatment. Journal of Gastroenterology. 2013;48(1):22-30.
- 18. Roeder C, Jordan S, Schulze Zur Wiesch J, et al. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. World J Gastroenterol. 2014;20(31):10984-10993.
- 19. Frei P, Leucht AK, Held U, et al; Swiss Hepatitis C Cohort Study Group. Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients. Liver Int.2014 Apr;34(4):551-7.
- 20. Nishikawa H, Iguchi E, Koshikawa Y, et al. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes. 2012;5:135.
- 21. Dimova RB, Zeremski M, Jacobson IM, et al. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta- analysis. Clin Infect Dis. 2013; 56(6):806-16.
- 22. Dore G, Hellard M, Matthews G, et al. Effective treatment of injecting drug users with recently acquired Hepatitis C virus infection. Gastroenterology. 2010;138(1):123.
- 23. Hellard M, Sacks-Davis R, Gold J. Hepatitis C Treatment for Injection Drug Users: A Review of the Available EvidenceClin Infect Dis. (2009) 49 (4): 561-573.
- 24. Kurelac I, Papic N, Sakoman S, et al. Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11(12):986-992.
- 25. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
- 26. Ghany MG, Nelson DR, Strader DB, et al. American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
- 27. Izumi N, Asahina Y, Kurosaki M. Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors. Hepatitis Research and Treatment. 2010;2010:703602.
- 28. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-490.
- 29. Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, et al. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol 2014; 20(13): 3443-3456.
- 30. Jonsson JR, Barrie HD, O’Rourke P, et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008 Jul;48(1):80-7.
- 31. Popescu CI, Riva L, Vlaicu O, et al. Hepatitis C Virus Life Cycle and Lipid Metabolism. Biology 2014, 3(4), 892-921.
- 32. Jung HJ, Kim YS, Kim SG, et al. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clinical and molecular hepatology 2014; 20(1): 38-46.
- 33. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Virahep-C Study Group. Associations Between Serum Lipids and Hepatitis C Antiviral Treatment Efficacy. Hepatology 2010;52(3):854-63.
- 34. Angelico F, Francioso S, Del Ben M, et al. Clinical trial: low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients. Aliment Pharmacol Ther 2009;30, 444-451.
- 35. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19 (Suppl. 1), 42-47.
- 36. Vespasiani-Gentilucci U, Gallo P, De Vincentis A, et al. A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World Journal of Gastroenterology : WJG. 2014;20(11):2825-2838.
- 37. Enjoji M, Kohjima M, Kotoh K, et al. Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C: Metabolic Strategies for Antiviral Treatments. International Journal of Hepatology, 2012, Article ID 264017, 7 pages, 2012.
- 38. Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology 2014 vol. 61 j S69-S78
- 39. Laurito MP, Parise ER. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. Braz J Infect Dis . 2013; 17( 5 ): 555-563.
- 40. Kiran Z, Zuberi BF, Anis D, et al. Insulin resistance in non-diabetic patients of chronic Hepatitis C. Pak J Med Sci 2013;29(1):201-204.